NPJ Logo

Digital biomarkers of cognitive function

Paul Dagum

This publication describes the study used to identify digital biomarkers that predict performance on gold standard neurocognitive tests.

RELATED CONTENT: Behind the Paper. This accompanying article describes the story behind Mindstrong’s technology, and the journey Paul Dagum, Founder and CEO, took to develop the pioneering concept and work.

book cover

Assessing Anhedonia with Quantitative Tasks, Digital and Patient Reported Measures in a Multi-Center, Double-Blind Trial With BTRX-246040 for the Treatment of Major Depressive Disorder

Annette Madrid, Daniel Smith, Sarah Alvarez-Horine, Kerensa Saljooqi, Paul Dagum, Atul Mahableshwarkar

This poster reports preliminary results from a Phase 2A trial of BTRX-246040, a potent and selective antagonist of the human nociception receptor (NOPR), as a treatment for anhedonia in patients with major depressive disorder. Mindstrong’s digital phenotyping is one of the outcome measures being used to assess efficacy.

Nature Logo

Join the Disruptors of Health Science

Thomas R. Insel

This Commentary describes the changing ecosystem as small and large tech companies become involved in biomedical research and healthcare.

Jama logo

Digital Phenotyping: Technology for a New Science of Behavior

Thomas R. Insel

This JAMA Viewpoint article describes digital phenotyping as a new technology for providing passive, objective, continuous information for diagnosing and monitoring mental illness.